“Stabilizing Rebound?” Vista Partners Daily Market Recap 8/6/19
Ten of 11 S&P 500 sectors moved higher today (energy dropped .1%) as the markets rebounded post-China’s overnight move to stabilize their previously precipitously declining currency, the yuan after the US Treasury Department called them out to be a currency manipulator.
Are we out of the woods yet?… I fear not as it is clear that we are not going to get an end to the US-China trade wars anytime soon and the games will continue to be played from both sides to gain a perceived or actual advantage. Expect increased volatility in the markets for the foreseeable future.
However, today the markets were up across the board. The S&P 500 gained back 37.03 points or 1.30% to end the session at 2,881.77 but still below the 3k level. The Dow closed back above the 26k level at 26,029.52 up 1.21% grabbing 311.78 points. The tech-heavy Nasdaq closed at 7,833.27 cruising up 1.39% or 107.23 points as techs tried to regain their stride. The Russell 2000, the small-cap stock market index representing the bottom 2,000 stocks in the Russell 3000 Index, closed at 1,502.09 adding 14.65 points or .99% today.
The recently soaring volatility bets retreated significantly. The CBOE Volatility Index (VIX) closed lower at $20.17/share down a whopping 17.97% or $4.42/share. The 2x leveraged ETF TVIX got clobbered too as it closed lower at $19.65/share down 12.94% or $2.92/share and traded between $19.60 and $22.96 today.
The U.S. Dollar Index moved up .1% today closing at 97.62.
The 2-yr treasury yield closed at 1.61% up another .3 points, and the 10-yr treasury yield closed even at 1.74% as the yield curve continued to flatten.
Oil prices fell another 1.5% closing at $53.84/bbl. Dow 30 energy participants Chevron (CVX) moved higher by .54% closing at $119.38/share & Exxon (XOM) closed higher by .97% closing at $70.96/share. Occidental Petroleum (OXY) closed at $47.58/share dropping 3.72%and sold $13 billion of debt to their Fund Anarko Purchase.
Gold prices closed at $1465.88/oz. Silver rose to $16.46/oz. Hecla Mining Company (HL)closed at $2.00 down .5% and is due to report earnings before the market opens on Aug. 7th. First Majestic Silver (AG) closed at $9.89/share down 1.30%.
Big tech stocks results were mostly positive today. Apple (AAPL) closed at $197.00/share up 1.89% & Twitter (TWTR) closed at $41.32/share up 2.35%. Facebook (FB) closed at $184.51/share up 1.53%, Alphabet (GOOG) closing at $1,169.95/share up 1.53% today. Shares of Microsoft (MSFT) closed trading at $134.69/share up 1.88%. Micron (MU) dropped 1.62% closing at $42.62/share & Intel (INTC) closed at $46.96/share up .65%.
Netflix (NFLX) moved up .80% ending at $310.10/share. NYC-based Yext (YEXT), an innovator in search giving customers control over their business information across the digital landscape, closed at $19.51/share down .91%. Yext has seen a 52-wk trading range of $12.90 – $27.19. 3M. (MMM) beat earnings expectations last Thursday and closed at $163.71/share losing .61%.
Large financial-related stocks fought their way back today too. Goldman Sachs (GS) closed at $206.01/share up 2.15%. JPMorgan Chase (JPM) closed at $110.43/share up .78%. Wells Fargo (WFC) closed at $46.93/share up by 1.71%. Morgan Stanley (MS) closed at $41.22/share up 1.80%, & Bank of America (BAC) closed at $28.42/share up 1.21%. Visa (V) closed at $172.48/share up 2.14%.
Institutional alternative asset manager Och-Ziff Capital Management Group (OZM) closed at $23.71/share down by 3.22% or $.79/share closing off its newly minted 52-wk high of $25.49. The 52-wk range is $8.60 – $25.49. OZM sports a 4.24% cash dividend. OZM reported their results last Friday and beat expectations.
Los Angeles-based Colony Capital (CLNY) a leading global investment management firm with assets under management of $43 billion had a interesting last few days as it announced last Thursday that it had acquired Digital Bridge Holdings LLC (“Digital Bridge”) for $325 million as part of Colony’s strategic evolution into the leading owner and investment manager of assets, businesses, and investment management products in which the digital and real estate frontiers intersect. The Digital Bridge acquisition follows the May 2019 final closing of Digital Colony Partners, a $4.05 billion fund sponsored by Colony and Digital Bridge. Digital Colony Partners is dedicated to global opportunities in digital infrastructure and is the largest first-time institutional fund of this type. This transaction seems to be bringing the world-class team of Digital Bridge investment professionals and management of the Digital Bridge portfolio of high performing assets under the Colony franchise. This acquisition continues Colony’s strategy of building leading investment management platforms, adding a powerful focus on assets and businesses that benefit from the increasingly digital world, including communications infrastructure, quant-driven listed securities products, artificial intelligence, digital credit products, smart logistics industrial, private equity and emerging markets infrastructure and growth equity strategies. Digital Bridge manages nearly $20 billion of digital infrastructure globally, directly and through Digital Colony Partners, and pro forma for Digital Colony Partners’ pending Zayo Group Holdings, Inc. transaction. Combining this portfolio with Colony’s footprint, the merged firm will manage approximately $60 billion of assets. The Company believes this concentration on digital infrastructure and related, digitally-driven investment management businesses will be a highly compelling strategy to generate substantial and sustainable value for shareholders and is very complementary to recent initiatives in other growth areas such as emerging markets, energy, and listed securities, often with a “new economy” emphasis. The combination of the two companies also paves the way for Colony’s leadership succession plans, which will be implemented over approximately 18 to 24 months. Following a transition period, Marc C. Ganzi, a founder and Chief Executive Officer of Digital Bridge, and a Managing Partner and an Investment Committee Member at Digital Colony, will become the CEO of Colony, succeeding Thomas J. Barrack, Jr., who will return to the position of Executive Chairman. Mr. Ganzi will focus with Mr. Barrack and the Colony board and executive team to continue Colony’s strategic plan of selling non-core assets, reducing G&A, growing investment management, generating liquidity and de-risking, and maintaining REIT status and a dividend – the further details of which will be announced before year-end. Read Complete Story. CLNY shares closed at $5.41/share flat on the day after hitting an intraday high of $5.48. CLNY pays a 7.79% cash dividend. The 52-wk range is $4.55 – $6.28. CLNY reports earnings on Friday, Aug. 9th.
Consumer Goods & Entertainment
It was a good overall day for most of the bigs in the consumer goods and entertainment sectors except for The Walt Disney Company (DIS) which actually moved up into the close finish at $141.87 but reported a miss on the bottom and top-line estimates after the close and the stock is showing to be currently off $4.67/share or $137.20.
The Home Depot (HD) closed at $208.80/share up 1.80%.
Nike (NKE) closed up 2.95% at $81.30/share. Nike recently missed analyst earnings estimates but maintained full-year guidance.
McDonald’s (MCD) closed at $214.08/share closing up 1.72%.
Walmart (WMT) closed at $107.27/share gaining 1.37%.
The Coca-Cola Company (KO) closed at $52.27/share up 1.20%.
The healthcare sector also rebounded today. The S&P 500 healthcare sector closed at 1041.18 adding back 1.27%. UnitedHealth (UNH) closed higher up 1.31% closing at $248.28/share, Walgreens Boots Alliance (WBA) closed at $51.45/share down .81% & Cigna (CI) gained nicely up 2.97% closing at $163.72/share post their recent Q2 earnings beat.
Johnson & Johnson (JNJ) recently reported earnings beating analyst expectations as they confirmed a +40% increase in Q2 net income year over year. JNJ shares closed at $130.77/share up .47% & continue to deal with the overhang of the opioid & mesothelioma related issues.
INVO Bioscience, Inc. (IVOB) ended the day at $.32170/share as daily trading volume continues to rise in concert with their announcing progress after their exclusive U.S. partnership with Ferring Pharmaceuticals, a leader in the reproductive health industry was announced in Q1-2019. Ferring has committed to providing the necessary sales and marketing resources to more fully develop the market in the United States. There are countless couples not able to receive reproductive treatments today, and Ferring can be instrumental in addressing the unmet needs of this cohort. Ferring has the industry experience, relationships and the marketing capabilities to successfully embed the INVOcell in clinics throughout the country. IVOB is a medical device company, headquartered in Sarasota, FL focused on creating simplified, lower-cost treatment options for patients diagnosed with infertility. The company’s lead product, the INVOcell, is a novel medical device used in infertility treatment that is FDA cleared and that enables egg fertilization and early embryo development in the woman’s vaginal cavity. IVOB also announced last week news of their recent appointment of Pressly Ahammed as the new Director of International Business Development and he will be responsible for the Company’s international distribution channels in Europe, Middle East, Africa & parts of Asia. Ahammed joined IVOB from Cooper Surgical where he held a similar position. See complete story. IVOB is due to report Q2 results prior to Aug. 15th. Q1 2019 results confirmed an outsized 82% jump in revenues compared to Q1 2018.
Corindus Vascular Robotics, Inc. (NYSE American: CVRS), a leading developer of precision vascular robotics, announced recently that Albert Einstein Jewish Hospital (Hospital Israelita Albert Einstein) in São Paulo, Brazil has become the first hospital in the Southern Hemisphere to implement Corindus’ CorPath GRX System. Ranked as the best hospital in Latin America for 10 years in a row, Albert Einstein Jewish Hospital will continue to uphold its standing by leveraging the Company’s technology in its health system’s leading research facilities. The Company’s CorPath® platform is the first FDA-cleared medical device to bring robotic precision to percutaneous coronary and vascular procedures. CorPath GRX is the second generation robotic-assisted technology offering enhancements to the platform by adding important key upgrades that increase precision, improve workflow, and extend the capabilities and range of procedures that can be performed robotically. For additional information, visit www.corindus.com CVRS shares rose sharply today closing at $2.54/share up 14.93% after hitting an intraday high of $2.61/share and a low of $2.21/share and the 52-week trading range is $.78- $3.49/share. Corindus is due to report earnings before the open on Thursday, Aug. 8th.
The Ishares Nasdaq Biotechnology ETF (IBB) gained 1.42% closing at $103.74. This sector has been on a more than healthy run over the last 30 days but & regained a bit of mojo after yesterday’s decline. The 52-wk range is $89.01 – $122.97.
Pfizer (PFE) close a bit lower at $36.95/share down .03%. They recently announced Q2 earnings and beat analyst expectations while simultaneously sharing that they will be merging its generic drug business Upjohn with Mylan (MYL) and then will seek to spinoff off the new combination into a separate publicly-traded company. Pfizer also recently announced the acquisition of Array BioPharma (ARRY) for ~$11.4 billion or $48/share in cash. See complete story.
The pharmaceutical giant and Dow component Merck & Co, Inc. (MRK) that recently announced the acquisition of Tilos Therapeutics for a consideration of up to $773 million closed at $84.35/share up 1.48% on the day as it recently received positive EU CHMP Opinion for ZERBAXA 3g Dose for the treatment of adults with hospital-acquired pneumonia (HAP), including ventilator-associated Pneumonia (VAP.)
Atossa Genetics (ATOS), a Seattle-based biotech firm developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions closed at $2.15/share up 2.38% today. The average daily trading volume is 442,807 shares per day. This week, Atossa announced that recently the online launch of company CEO Steven Quay’s Tedx UofW Talk, “How to Be Smart When You’re Dense: Preventing Breast Cancer by 2030.” The talk has been posted online at https://www.youtube.com/watch?v=hK4PlbYE_5M&list=PLsRNoUx8w3rNCo4uCVXiNDFZLiKrIOQ1J&index=5 and can also be accessed via the company’s website at www.atossagenetics.com. In the Tedx UofW talk, Steven Quay, M.D., Ph.D., Atossa’s Chief Executive Officer outlines the journey of Atossa Genetics in identifying improved ways to identify women at high risk of breast cancer, using mammography to identify dense breast tissue. Dr. Quay also details his experience with triumph, failure, and perseverance while trying to prevent one of the world’s most common diseases: breast cancer. He emphasizes the need for unshaken efforts to solve such complex problems and ways that he and his team are doing so in breast cancer research. Also, recently Atossa is developing a new proprietary modified-release oral tablet form of its Endoxifen, which is the form of the drug that the company intends for future clinical studies and commercialization. This is the next generation of oral Endoxifen following the successful clinical studies of the capsule form of the company’s oral Endoxifen. A patent application covering the new table has also been filed with the U.S. Patent and Trademark Office. As part of the development of this new oral tablet, Atossa has commenced a Phase 1 study in Australia to ascertain the pharmacokinetics of the tablet. The study is randomized, double-blinded and placebo-controlled with both single and multiple-doses in 2 groups with a total of 24 healthy female volunteers who will be dosed for 14 days. Atossa’s oral Endoxifen capsule, which has been used in previous clinical studies, will serve as the comparator. The first group of the study has now been enrolled and dosed. Steven C. Quay, Ph.D., M.D., CEO, and president of Atossa, commented: “We are excited to take this next step in our oral Endoxifen product development. Based on the abundance of information from our previous clinical studies, we strongly believe in the potential efficacy of oral dosing and intend for this modified-release tablet to be the commercial form of our oral Endoxifen. The goal of the modified-release aspect of the drug is to create more even uptake of the drug which we believe may reduce side effects and improve efficacy. This new study builds on the success of our Phase 1 studies of the oral capsule and topical forms of our Endoxifen, our recent successful Phase 2 study of topical Endoxifen, which demonstrated significant efficacy in reducing breast density, and our single-patient compassionate use study of oral Endoxifen. Following the completion of this Phase 1 trial, we will continue to use this proprietary modified-release formulation for future clinical studies — including a Phase 2 trial that we have already indicated is in development — and ultimately regulatory approval. We look forward to completing the study in the next quarter.”
San Diego-based biotech Fate Therapeutics (NASDAQ: FATE), dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, closed at $19.82/share up 2.85% on 557,053 shares of trading after recently establishing a new all-time intraday high of $22.82! The 52-week range is $8.64 – $22.82. FATE reported business highlights and financial results for the second quarter ended June 30, 2019 today. Scott Wolchko, President and Chief Executive Officer of Fate Therapeutics stated, “The early safety and tolerability signals observed in patients receiving multiple doses of FT500, the first iPSC-derived cell therapy to undergo clinical investigation in the United States, are very encouraging. The ability to cost-effectively mass-produce a universal cell-based cancer immunotherapy, and to safely deliver that therapy ‘on-demand’ in multiple doses, has the potential to transform outcomes for many patients. We continue to be very pleased with the Company’s rapid pace of innovation, product development and leadership in bringing iPSC-derived cell-based immunotherapies engineered with potent anti-tumor functionality to cancer patients. Our first engineered iPSC-derived NK cell product candidate, FT516, is ready for Phase 1 clinical evaluation following successful completion of cGMP production, and the IND application for our multi-antigen targeted CAR19 NK cell product candidate, FT596, has been submitted to the FDA. Additionally, with the renewal of our collaboration with Memorial Sloan Kettering Cancer Center for the development of iPSC-derived T-cell immunotherapies, we are well-positioned to continue to lead the field in the development of off-the-shelf CAR T-cell therapy.” Cantor Fitzgerald initiated coverage on FATE on July 22nd with an overweight rating. Oppenheimer initiated coverage on Friday, July 12th with an Outperform Rating. Guggenheim Securities initiated coverage on FATE recently with a “Buy Rating” and a $25/share price target. Mizuho initiated coverage with a price target of $27/share within the last 30 days.
Bedford, Massachusetts-based Stoke Therapeutics is a biotechnology company pioneering a new way to treat the underlying cause of severe genetic diseases by precisely upregulating protein expression. Recently Stoke Therapeutics announced the pricing of its initial public offering (IPO) of 7,891,110 shares of its common stock at a price to the public of $18.00 per share. The shares are now trading on The Nasdaq Global Select Market as of June 19, 20,19 under the symbol “STOK.” Stoke’s stock traded as high as $31.76 recently a new all-time high prior to closing trading at $26.45/share up 4.50%. See complete story.
Xeris Pharmacueticals, Inc. (XERS) closed down 1.87% closing at $9.96/share. Xeris is a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations.
Recent IPO Update
Elsewhere on the recent IPO front-most had a decent move higher today. Zoom Video Communications (ZM) moved up by .83% closing at $90.43/share & Uber Technologies (UBER), the ride-sharing company closed higher by .26% at $39.15/share & still below its recent IPO price of $45. However, plant-based burger maker Beyond Meat (BYND) closed lower at $161.24/share down a significant bite of 8.36% after establishing a new all-time high of $239.71/share recently. Their meat is made of four main ingredients: water, pea protein isolate, canola oil & refined coconut oil and is meant to taste like “meat” and this rise feels euphoric. Slack Technologies (WORK) which jumped into the public markets with their IPO recently flying up 48.5% from their offering price of $26/share & closed today at $30.84/share down 1.75%. Slack is a provider of a cloud-based workplace messaging app and went public via a direct listing avoiding paying fees to the relevant banks.
Last Friday we confirmed that non-farm payroll additions came in at 164,000 in July. The unemployment rate is at 3.7% but 3.6% was expected. Wage gains grew by 3.2%vs the 3.1% expected rate. The end of July reading for the University of Michigan Index of Consumer Sentiment clocked in at 98.4 and all things seem to be good still to consumers. The trade deficit for June was at $55.2 billion as imports fell more than exports. Factory orders rose .6% in June.
Yesterday, the ISM Non-Manufacturing Index came in and decreased to 53.7% in July down from 55.1% in June, now curiously at its lowest level in nearly three years.
Today, we received Job Openings report for June showing a move higher to 7.348 million.
Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.
Stay Informed! Stay Competitive! Sign Up to receive FREE email updates here!